In addition to the direct effect of c-MET inhibitors on tumour growth and invasion, treatment with c-MET inhibitors foretinib, crizotinib and cabozantinib are demonstrated to reduce the viability of vascular endothelial cells immortalised from melanoma tumours grown in immunocompetent mice (Jenkins et al., 2021), revealing the potential efficacy of c-METi on tumour cells, stromal cells and CTCs. Here, MET is linked to melanoma.